Abstract
Results of the treatment of inoperable non-small cell lung cancer are unsatisfactory. This study presents the results of chemoradiation treatment with accelerated hyperfractionated regime with uneven crushing daily dose in these patients.
Methods: The study included 187 patients with histology confirmed diagnosis of II –III stage non-small cell lung cancer. Patients were divided into three groups: the first (A) group included 75 patients who underwent radiotherapy in conventional regimen (60-66 Gy in 30-33 daily fractions) with sequential 2-4 cycles of chemotherapy (cisplatin plus etoposide). In the second (B) group - 66 patients who underwent radiation therapy to hyperfractionated accelerated regimen (two day fractions with 5-6 hours interval 1 Gy and 1.5 Gy in 48-56 fractions) with sequential 2-4 cycles of chemotherapy of cisplatin plus etoposide. The third (C) group - 46 patients who underwent radiation therapy in hyperfractionated accelerated regimen (1 Gy and 1.5 Gy in 48-56 fractions) with simultaneous 2 cycles of cisplatin plus etoposide and 2 cycles consolidation chemotherapy.
Results: Complete and partial response rate was 60.0% in the A group, 89.4% in the B group and 76.0% in the C group. Five-year overall and five-year progression-free survival rates were in A, B and C groups, 6.6%, 10.5%, 21.4% and 2.5%, 10.1%, 16.4%, respectively. Frequency of radiation esophagitis and pneumonitis was insignificantly higher in group B and C.
Conclusion: Accelerated hyperfractionated radiotherapy with simultaneous chemotherapy is more effective then traditional radiotherapy in non-small cell lung cancer with low levels of toxicity.
- Copyright ©ERS 2015